Regional Intervention of Stroke Care to Increase Thrombolytic Therapy for Acute Ischemic Stroke
The Southeast Texas Experience
Background and Purpose—The aims of this study were to investigate the effect of an intervention to unblind data on r-tPA (recombinant tissue-type plasminogen activator) administration and sharing data with chief executive officers of participating hospitals, on r-tPA administration rates postintervention and on potential healthcare cost savings implemented at 26 Southeast Texas Regional Advisory Council hospitals.
Methods—Retrospective analysis of prospective data on thrombolytic therapy from 26 Southeast Texas Regional Advisory Council hospitals, collected between April 2014 and June 2016. The control (blinded) period (Q2-2014 to Q2-2015) was followed by unblinding (Q3-2015).
Results—Intervention was associated with 21.1% increase in r-tPA administration rates, with 38.5% increase in r-tPA administration with door-to-needle time ≤60 minutes. An absolute increase in r-tPA administration of 2.1% was seen with an average lifetime cost savings of $3.6 million.
Conclusions—Transparent regional data sharing was associated with improved r-tPA administration and healthcare cost savings.
- Received January 8, 2018.
- Revision received June 4, 2018.
- Accepted June 12, 2018.
- © 2018 American Heart Association, Inc.